BeOne Medicines Ltd
56 hedge funds and large institutions have $645M invested in BeOne Medicines Ltd in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 9 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $504M → $645M (+$140M)
4% more funds holding
Funds holding: 54 → 56 (+2)
0.1% more ownership
Funds ownership: 3.3% → 3.4% (+0.1%)
Top Buyers
Top Sellers
ONC Hedge Fund Activity: Q1 2017 in Review
56 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q1 2017, worth a combined $645M — up 28% from $504M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ONC positions and 9 closed out — a net gain of 4 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Myriad Asset Management, opening a new position worth an estimated $12M. The largest seller was Fosun International, cutting an estimated $3.81M.
- 56 institutional investors held BeOne Medicines Ltd (ONC) as of Q1 2017, up from 54 in Q4 2016.
- Funds reported $645M of BeOne Medicines Ltd stock for Q1 2017, up 28% quarter-over-quarter.
- 13 funds opened new BeOne Medicines Ltd positions in Q1 2017 and 9 closed out, a net change of +4 holders.
- The largest BeOne Medicines Ltd buyer in Q1 2017 was Myriad Asset Management, an estimated $12M added.
- The largest BeOne Medicines Ltd seller in Q1 2017 was Fosun International, an estimated $3.81M sold.
Based on aggregated 13F filings for Q1 2017.